AI-Based Remote Test for Parkinson’s Disease Severity Shows Promise

By Michael Awood

September 17, 2023

People with Parkinson’s disease rarely receive proper care because of a lack of access to neurological care. In the US, about 40% of those aged 65 or older with PD do not receive care from a neurologist. Access is even more limited in developing regions. Experts suggest an AI-based method to measure Parkinson’s disease severity using a remote finger-tapping test.

Researchers developed a model that uses AI techniques to evaluate motor performance severity of patients. Through performing finger-tapping tasks at home, they analysed the patients with a webcam. A panel of experts and non-experts validated its features, which correlated strongly with the experts’ ratings.

This research shows that remote assessment of the finger-tapping task can be done with reliability. AI models have the potential to perform as well as clinicians and outperform non-specialists in assessing the task, according to the study. The model had an equal performance for all subgroups, suggesting its potential wide adoption in movement disorders.

The tool could enable longitudinal tracking of symptom progression, helping to fine-tune PD treatment. Clinical visits can use it to track PD progression and augment neurologists’ ability to analyze videos with digital biomarkers. In areas with a scarcity of neurologists, the tool could assess symptoms frequently and refer the patient to a neurologist if necessary.

However, the model was not without its limitations. Sometimes, it misclassified severity scores and showed poor accuracy. The model worked well in both high and low-quality videos, making it difficult to evaluate videos taken outside clinical settings. Researchers emphasised ethical considerations as data security, user privacy, and algorithmic bias. When introducing the tool in healthcare settings, these need reviewing.

The researchers also suggest future improvements. These included addressing the impact of tremors on finger-tapping, increasing the sample size, and balancing severity scores as a few improvements to the study.

 

Cover image taken from the research article

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.